Loading…
Employees: 507
Size i3system (214430.KS) is a South Korea Health Care company (Medical Specialties) with a market value of $287M, the 476th largest of 495 South Korea companies the cockpit tracks. Shares closed at ₩53,900 on 6 Nov 2026.
Performance Over six months the shares fell 48.2%, against -8.2% for the median peer and -24.5% for the South Korea market (cap-weighted) — lowest of 21 in its peer set.
Growth Revenue grew 8.4% over the last twelve months (peer median +5.2%); the operating margin is 12.9% (peer median 4.1%).
Valuation It trades at 2.5× enterprise value to sales against a peer median of 3.7× (9th cheapest of 21).
Capital Return on invested capital runs 5.8 points above its cost of capital (7.7% WACC).
Next results Next results expected around 18 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩133B | ₩124B | ₩121B | ₩122B | ₩83.8B |
| Revenue growth | — | +3% | -1% | +45% | — |
| Gross profit | ₩39.1B | ₩36.5B | ₩31.9B | ₩23.0B | ₩13.9B |
| EBITDA | ₩22.6B | ₩21.1B | ₩19.9B | ₩17.0B | ₩10.2B |
| Net income | ₩17.2B | ₩18.8B | ₩15.0B | ₩12.6B | ₩6.18B |
| Free cash flow | -₩5.18B | ₩4.01B | ₩2.86B | ₩14.5B | -₩4.14B |
| Capital expenditure | ₩18.0B | ₩14.9B | ₩5.34B | ₩7.35B | ₩3.56B |
| Total debt | ₩8.68B | ₩8.99B | ₩10.7B | ₩3.84B | ₩5.99B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 214430.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -32.0% | -5.6% | lowest of 21 |
| 6-month return | -48.2% | -8.2% | lowest of 21 |
| Distance from 52-week high | -60.9% | -30.0% | lowest of 21 |
| Revenue growth (TTM) | +8.4% | +5.2% | 9th highest of 21 |
| Operating margin | 12.9% | 4.1% | 8th highest of 21 |
| EV / Sales | 2.5× | 3.7× | 9th cheapest of 21 |
| ROIC minus cost of capital | +5.8 pp | -3.9 pp | 6th highest of 19 |
| EV / EBITDA | 14.9× | 11.4× | 3rd most expensive of 11 |
| Net debt / EBITDA | -2.3× | 1.3× | 6th least indebted of 12 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| i3system 214430.KS | South Korea | $287M | -48% | +8% | 13% | 2.5× | n/a | n/a |
| i-SENS 099190.KS | South Korea | $268M | -42% | +7% | 4% | 1.1× | n/a | n/a |
| Improve Medical Instruments 300030.SZ | China | $320M | -17% | -2% | 4% | 4.2× | 26.0% | -11.9% |
| Orthofix Medical OFIX | United States | $321M | -32% | +3% | -4% | 0.6× | n/a | n/a |
| Japan Eyewear 5889.T | Japan | $321M | -7% | +15% | 32% | 3.1× | -9.0% | +20.2% |
| Surgical Science Sweden SUS.ST | Sweden | $321M | +86% | +8% | 16% | 2.4× | 4.3% | +56.8% |
| Kontour (Xi'an) Medical Technology 688314.SS | China | $321M | -39% | +4% | 27% | 5.3× | 6.1% | +16.4% |
| Tauns Laboratories 197A.T | Japan | $322M | -2% | -23% | 29% | 4.8× | n/a | n/a |
| Jiangsu Nanfang Medical 603880.SS | China | $336M | +4% | -7% | -15% | 4.7× | 22.5% | -10.9% |
| CapsoVision CV | United States | $336M | -11% | +15% | -217% | 23.6× | n/a | n/a |
| Peijia Medical 9996.HK | Hong Kong | $340M | -34% | +21% | -13% | 2.9× | n/a | n/a |
| Stratec SBS.DE | Germany | $341M | +41% | -3% | 3% | 1.6× | n/a | n/a |
| Orchestra BioMed OBIO | United States | $341M | +41% | +986% | -181% | 9.8× | n/a | n/a |
| Chemclin Diagnostics 688468.SS | China | $342M | -23% | -14% | 6% | 6.2× | 31.9% | -4.5% |
| BioNote 377740.KS | South Korea | $343M | -10% | +13% | 16% | 0.8× | -19.8% | -28.5% |
| ACRO Biomedical 6748.TWO | Taiwan | $347M | +129% | +45% | -178% | 200.7× | n/a | n/a |
| Embecta EMBC | United States | $351M | +70% | -8% | 26% | 1.6× | -19.9% | -0.1% |
| Shenzhen Bioeasy Biotechnology 300942.SZ | China | $352M | -27% | +12% | -2% | 8.1× | n/a | n/a |
| Chongqing Xishan Science and Technology 688576.SS | China | $356M | -26% | -23% | -29% | 6.5× | n/a | n/a |
| COLTENE CLTN.SW | Switzerland | $361M | +3% | -2% | 8% | 1.4× | 0.1% | -0.7% |
| IVF HARTMANN VBSN.SW | Switzerland | $364M | -5% | +7% | 14% | 1.1× | -12.7% | -1.3% |